144
Views
7
CrossRef citations to date
0
Altmetric
Review

Cefditoren in upper and lower community-acquired respiratory tract infections

, &
Pages 85-94 | Published online: 09 Feb 2011

Abstract

This article reviews and updates published data on cefditoren in the evolving scenario of resistance among the most prevalent isolates from respiratory tract infections in the community (Streptococcus pyogenes, Haemophilus influenzae, and Streptococcus pneumoniae). By relating the in vitro activity of cefditoren (in national and multinational surveillance and against isolates with emerging resistant genotypes/phenotypes) to its pharmacokinetics, the cefditoren pharmacodynamic activity predicting efficacy (in humans, animal models, and in vitro simulations) is analyzed prior to reviewing clinical studies (tonsillopharyngitis, sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia) and the relationship between bacterial eradication and clinical efficacy. The high in vitro activity of cefditoren against the most prevalent respiratory isolates in the community, together with its pharmacokinetics (enabling a twice daily regimen) leading to adequate pharmacodynamic indexes covering all S. pyogenes, H. influenzae, and at least 95% S. pneumoniae isolates, makes cefditoren an antibiotic that will play a significant role in the treatment of respiratory tract infections in the community. In the clinical setting, studies carried out with cefditoren showed that treatments with the 400 mg twice daily regimen were associated with high rates of bacteriological response, even against penicillin-nonsusceptible S. pneumoniae, with good correlation between bacteriological efficacy/response and clinical outcome.

Scenario for new antibiotics for the treatment of respiratory tract infections

Infections, mainly respiratory tract infections,Citation1 are the most frequent reason for seeking medical attendance in the community.Citation2 Around 85% to 90% of global antibiotic consumption occurs in the community, with 80% of this consumption for the treatment of respiratory tract infections.Citation3 Streptococcus pyogenes causing pharyngotonsillitis, and Streptococcus pneumoniae and Haemophilus influenzae causing otitis and lower respiratory tract infections (acute exacerbations of chronic bronchitis and community-acquired pneumonia), are the most prevalent isolates in community-acquired respiratory tract infections, and can be considered index bacteria for assessing antibiotic resistance.

Several studies carried out in Spain have shown that antibiotic consumption is the main reason for resistance selection in the community.Citation4 These studies related consumption of β-lactams (mainly second-generation oral cephalosporins) and macrolides (mainly long half-life macrolides) with penicillin/erythromycin resistance in S. pneumoniae (with temporalCitation5 and geographicalCitation6 associations) and with ampicillin/amoxicillin resistance in H. influenzae (this study showed higher accountability for aminopenicillins with or without clavulanic acid).Citation7 Other studies showed that macrolide consumption (mainly long half-life macrolides) was linked to erythromycin resistance in S. pyogenes.Citation8,Citation9

The Spanish data show that the analysis of resistance in the community should be seen as a global problem, since geographical and temporal relationships between resistance in these target bacteria have been described, leading to the concepts of co-resistance selection and co-selection of resistance. Due to co-resistance selection, there is a significant association between penicillin and erythromycin resistance in S. pneumoniae,Citation10,Citation11 and because of the co-selection of resistance, the penicillin/erythromycin resistance in S. pneumoniae is associated with ampicillin resistance in H. influenzae.Citation10 Further, this resistance in S. pneumoniae and in H. influenzae is significantly related to erythromycin resistance in S. pyogenes from a geographical perspective.Citation10 The geographical relationship between macrolide resistance in S. pneumoniae and in S. pyogenes in Spain emphasizes the idea of resistance as a global problem, since S. pneumoniae is isolated mainly from adults, from lower respiratory tract samples, with MLSB as the prevalent resistance phenotype, while S. pyogenes is isolated mainly from children, from pharyngotonsillitis, with M-efflux as the prevalent resistance phenotype.Citation10,Citation11

The need for new antibiotics is defined mainly by their antimicrobial activity against the prevalent resistance phenotypes, rather than the activity against phenotypes susceptible to antibiotics previously used in the community. The analysis of resistance prevalence and phenotypes reported in index bacteria will define the context in which new antibiotics should demonstrate in vitro activity.

S. pyogenes

S. pyogenes is highly susceptible to penicillin (strains with minimum inhibitory concentration [MIC] >0.12 μg/mL have not been found) and should be considered susceptible to all β-lactams. In contrast, resistance to erythromycin is widely reported, with geographical variations in prevalence rates and predominant resistance phenotypes. The rate of erythromycin resistance in S. pyogenes varies among countries, from 6.9% in the US (56% MLSB phenotype)Citation12 to 25.6% in Hong Kong.Citation13 In a recent study performed in Eastern Europe, the rate of erythromycin resistance in S. pyogenes was low (<10%) in Romania and Baltic countries, intermediate (10%–20%) in Poland and the Czech Republic, and high (>25%) in Hungary and Slovakia.Citation14 The predominant (75%) resistance phenotype was MLSB (58.9% of the constitutive phenotype plus 16.1% of the inducible phenotype).Citation14 In Spain, although the rates of erythromycin resistance have decreased in SAUCE (Susceptibility to the Antimicrobials Used in the Community in España) studies over recent years (26.7% in 1996–1997, 20.4% in 1998–1999, 24.3% in 2001–2002, and 19.0% in 2006–2007), no temporal decreasing trend for erythromycin resistance was found in contrast to an increasing trend in the percentage of the MLSB phenotype (7.0%, 10.5%, 14.0%, and 35.5%, respectively, among resistant strains in the corresponding SAUCE studies).Citation15

Since both mechanisms of resistance (M-efflux and MLSB) imply resistance to 14- and 15-membered macrolides, erythromycin resistance implies resistance to azithromycin and clarithromycin.Citation16

H. influenzae

Resistance to β-lactams in H. influenzae is defined using ampicillin as a marker of resistance. Most ampicillin-resistant isolates are β-lactamase producers: TEM-1, TEM-2 and, with lower frequency, ROB-1. The remaining ampicillin-resistant isolates are resistant due to mutations in the ftsI gene causing alterations in the amino acid sequences of penicillin-binding protein 3 (PBP3). Resistance phenotypes showing mutations in the ftsI gene are BLNAR (β-lactamase negative ampicillin resistant) and BLPACR (β-lactamase positive amoxicillin/clavulanic acid resistant), which exhibits both resistance mechanisms (β-lactamase production and mutations in the ftsI gene). These phenotypes should be considered also resistant to amoxicillin/clavulanic acid, ampicillin/sulbactam, piperacillin/tazobactam, cefaclor, and cefuroxime.Citation17

The epidemiology of ampicillin resistance varies geographically and temporally. In a global surveillance including 15 countries (in 2003–2004), ampicillin resistance ranged from 8.7% in South Africa to 29.6% in Asia.Citation18 In the US, ampicillin resistance averaged about 30% in the period 2001–2005.Citation19 In a European surveillance (2004–2005) including isolates from 11 countries, mean ampicillin resistance was 16.4%, resistance due to β-lactamase production ranging from 17.6% in France to 0% in Germany and Netherlands, and BLNAR isolates ranging from 33.9% in Spain to 0% in France and Netherlands.Citation20 In Spain (SAUCE studies: 1996–1997, 1998–1999, 2001–2002, 2006–2007) ampicillin resistance seems to be decreasing over time (38.6%, 30.0%, 25.1%, and 16.1%, respectively), both resistance due to β-lactamase production (25.7%, 23.0%, 20.0%, and 15.7%, respectively) and to the BLNAR phenotype (13.5%, 12.0%, 4.4%, and 0.7%, respectively).Citation15 However the rate of BLNAR and BLPACR among strains exhibiting high MIC of ampicillin (≥1 μg/mL) or amoxicillin/clavulanic acid (≥2/1 μg/mL) is higher, as shown in a Spanish multicenter study carried out in 2005–2007 where among the 196 strains with high MICs identified, 165 showed mutations in the ftsI gene (73% BLNAR and 27% BLPACR).Citation21 The situation in Japan is the most worrisome since in nationwide global surveillances the percentage of BLNAR and BLPACR strains was 29.1% and 6.7%, respectively, in adults in 2007Citation22 and 59.3% and 6.4%, respectively, in children in 2004.Citation23

According to the SAUCE study in 2006–2007, similar susceptibility rates to ampicillin or amoxicillin/clavulanic acid were obtained by applying CLSI (Clinical and Laboratory Standards Institute) and PK/PD breakpoints (pharmacodynamic [PD] breakpoints predicting eradication that are obtained through the relationship between pharmacokinetic [PK] parameters and MIC).Citation15 In contrast, rates of susceptibility to cefaclor changed from 97.8% (by applying CLSI breakpoints) to 25.8% (PK/PD breakpoints).Citation15 Similarly, percentages of susceptibility to macrolides were high by applying CLSI breakpoints (99.3% and 100% to clarithromycin and azithromycin, respectively) but sharply decreased to 5.1% and 23.8%, respectively, when PK/PD breakpoints were considered,Citation15 probably due to the presence of efflux pumps in virtually all H. influenzae strains. This suggests that current CLSI breakpoints for H. influenzae for macrolides should be reviewed.Citation24

S. pneumoniae

Except for fluoroquinolones (worldwide nonsusceptibility rates to levofloxacin are as low as <2.5%Citation25), antibiotic resistance in S. pneumoniae also depends on geographic location and time, antibiotic pressure (consumption) and the introduction of the 7-valent conjugate vaccine (PCV7 including serotypes most associated with penicillin/erythromycin nonsusceptibility) being the principal influencing factors. In a worldwide surveillance study, penicillin nonsusceptibility was 66% in South Africa, 47.3% in Asia-Pacific, 44.1% in the Middle East, 42.1% in North America, 37.9% in Latin America, and 27.9% in Europe.Citation26 Penicillin (with CLSI-defined breakpoints for oral penicillin) is the best epidemiological marker since nonsusceptibility rates to β-lactams and to macrolides are clustered in penicillin-intermediate and/or in penicillin-resistant S. pneumoniae.Citation27 In this sense, in a 2001–2002 surveillance study (mainly including noninvasive isolates) in Spain the reported nonsusceptibility rates to β-lactams and macrolides were around 0% and 15%, respectively, among penicillin-susceptible strains, around 80% for cefaclor, 50% for cefuroxime axetil, and 60% for macrolides among penicillin-intermediate strains, and around 35% for amoxicillin/clavulanic acid, 100% for cefaclor and cefuroxime axetil, 15% for cefotaxime, and 60% for macrolides among penicillin-resistant strains.Citation27

Focusing on invasive isolates, the increase in the prevalence of certain serotypes and of penicillin nonsusceptibility, which was reported in the 1980s and 1990s in relation to antibiotic consumption, reversed in the 2000s when PCV7 was introduced for immunization of children.Citation28,Citation29 The introduction of PCV7 has not only dramatically reduced the incidence of invasive pneumococcal disease but also markedly decreased PCV7 serotypes, thus affecting the rate of penicillin and erythromycin nonsusceptibility in invasive isolates both from children and adults.Citation29,Citation30 The SAUCE studies in Spain (1996–1997, 1998–1999, 2001–2002, 2006–2007) have shown a decreasing trend for penicillin nonsusceptibility rates (60.0%, 50.2%, 43.9%, and 22.9%, respectively) in contrast to erythromycin nonsusceptibility, which has shown lower variations (36.5%, 34.9%, 34.5%, and 22.9%, respectively), the MLSB resistance phenotype decreasing over time (from 98.4% in 1996–1997 to 81.3% in 2006–2007). Of all invasive isolates received in the Spanish Reference Laboratory for Pneumococci in 2009, 85.3% belonged to serotypes not included in PCV7, around 20% being nonsusceptible to penicillin (≈50% of them serotype 19A).Citation31 Although serotypes 1 and 19A showed significant increasing trends, only serotype 19A was linked to penicillin nonsusceptibility.Citation31Citation33 In this sense, in parallel to the increasing trend for serotype 19ACitation28,Citation32 there was an increasing trend for penicillin nonsusceptibility in serotype 19ACitation28 which reached around 80% in 2008 and was associated with amoxicillin and cefotaxime nonsusceptibility in around 20% of isolates.Citation32

The emergence of amoxicillin resistance in pre-existing penicillin-resistant clones has been reported among PCV7 and non-PCV7 serotypes,Citation34,Citation35 with troublesome clones (Spain23F-1, Spain9V-3, Spain6B-2 and Spain14-5) exhibiting MIC values of amoxicillin higher than of penicillin.Citation34 In addition, in 2008 a published article described in 9 Romanian isolates of the sequence type ST321 (or the nearest matched type with only a single or double locus variance), belonging to serotypes 23F or 19A, the presence of a new cluster in regions 595–600 of PBP2X together with a new murM allele (with absence of mutations in the conserved domain of PBP1A).Citation35 These isolates showed MICs of penicillin, amoxicillin, and cefotaxime of ≥16 μg/mL,Citation35,Citation36 representing a breakthrough increase in the magnitude of resistance to β-lactams.

Also of great concern is the existence of isolates showing multiple resistance defined as full resistance to 2 or more of the 6 classes of antibacterials represented by penicillin, erythromycin, cefuroxime, tetracyclines, trimethoprim/sulfamethoxazole, and levofloxacin. Multiple resistance in S. pneumoniae has been reported at rates as high as 19.1% in North America, 27.7% in Western Europe, and 80.4% in the Far East.Citation25

According to the SAUCE study in 2006–2007, no differences in susceptibility rates were found by applying PK/PD and CLSI breakpoints, with susceptibility rates to macrolides of ≈80%, to amoxicillin/clavulanic acid of ≈95%, to cefuroxime axetil of ≈95%, and to cefotaxime of ≈100%.Citation15

Cefditoren: in vitro activity, pharmacokinetics, and pharmacodynamics

Cefditoren is the active form of cefditoren pivoxil, an oral third-generation aminothiazolyl cephalosporin with structural components similar to those of first- and third-generation cephalosporins.Citation37 In cefditoren, the group attached at the C-7 position of the cephem skeleton affords activity against Gram-negative microorganisms, whereas the one attached at the C-3 position (not seen in other nonfirst-generation cephalosporins) affords activity against Gram-positive bacteria.Citation37 According to the study by Yamada et al on the structure of the PBP2X of S. pneumoniae complexed with cefditoren, the unique methylthiazole group of the C-3 side chain of the cephem skeleton fits well into the PBP binding pocket, a feature that is likely to play a role in the high activity of cefditoren against S. pneumoniae.Citation38

In vitro activity

Cefditoren exhibited high intrinsic activity against S. pyogenes, with MIC50/MIC90 values of ≤0.03/≤0.03 μg/mL, both against macrolide-susceptible or -resistant strains, in a multicenter, multinational study performed in Europe.Citation14 The intrinsic activity of cefditoren was similar against H. influenzae (MIC50/MIC90 = ≤0.03/≤0.03 μg/mL), as shown in a study carried out in 8 Central and Eastern European countries in 2005–2006.Citation39 This in vitro activity against H. influenzae was not influenced by the phenotype/genotype of the isolates, with similar intrinsic activity to cefotaxime against ampicillin-susceptible, beta-lactamase positive, BLNAR, and BLPACR strains (MIC90 values ranging from ≤0.015 to 0.06 μg/mL).Citation21,Citation40

For S. pneumoniae the multicenter, multinational ARISE study carried out in Europe in the pre-PCV7 era (thus including a large number of isolates from serotypes 6, 9, 14, and 23, traditionally linked to resistance) showed MIC50/MIC90 values of cefditoren of ≤0.03/0.5 μg/mL.Citation41 After PCV7 introduction the prevalence of vaccine serotypes greatly decreased (together with a decrease in penicillin nonsusceptibility),Citation28,Citation29 and in the most recent SAUCE study (2006–2007) MIC50/MIC90 values of cefditoren were ≤0.015/0.125 μg/mL.Citation15 In parallel there has been a high increase in the prevalence of non-PCV7 serotypesCitation28,Citation29 which occupied the niche left by PCV7 serotypes, leading to a prevalence of 85.3% of non-PCV7 serotypes isolates among invasive isolates in 2009 in Spain.Citation31 Of these, 80% were susceptible to penicillin (MIC90 of cefditoren ≤0.06 μg/mL) and 20% were nonsusceptible (of these, 56.3% for serotype 19A, 9.8% for serotype 24F, 7.0% for serotype 35B, 5.4% for serotype 6A, and 4.4% for serotypes 11A, 15A, and 23B each).Citation31 The intrinsic activity of cefditoren against these penicillin nonsusceptible non-PCV7 serotypes varied on serotype basis: MIC90 of 1 μg/mL for penicillin-resistant and 0.5 μg/mL for penicillin-intermediate serotype 19A isolates, 0.5 μg/mL for serotype 11A, 0.25 μg/mL for serotypes 35B, 6A, and 15A, 0.12 μg/mL for serotype 24F and 0.06 μg/mL for serotype 23B isolates.Citation31

The intrinsic activity of cefditoren was markedly higher than that of other β-lactams against isolates with resistance patterns highly troubling as strains belonging to clones Spain23F-1, Spain9V-3, Spain6B-2, and Spain14-5. Against these strains cefditoren showed MIC90 values ≤1 μg/mL, 1 dilution lower than values for cefotaxime.Citation34 The intrinsic activity of cefditoren against the exceptional strains of sequence type ST321 (serotypes 23F or 19A) with a new cluster in regions 595–600 of PBP2X and a new murM allele warrants special attention.Citation35 These isolates, representing the isolates most resistant to β-lactams described in the literature, were inhibited by 2 μg/mL of cefditoren in contrast to MICs ≥ 16 μg/mL of penicillin, amoxicillin, and cefotaxime.Citation35

No inoculum effect was observed with cefditoren when testing several clinical isolates of S. pneumoniae and H. influenzae by determining its in vitro activity using inoculum sizes of 104 to 105 colony forming units (cfu)/mL compared with the one obtained with inocula of 107 to 108cfu/mL.Citation42

Pharmacokinetics

When orally administered to humans the prodrug cefditoren pivoxil is completely and rapidly hydrolyzed to cefditoren, the bioavailability being low in the fasting state (15%–20%). However when administered after high fat meals the bioavailability of cefditoren increases, Cmax and AUC values being 50% and 70%, respectively, higher than those determined in the fasting state.Citation37 In a phase I study in Caucasians administed 400 mg cefditoren pivoxil single dose in the fed state, Cmax was 3.7 ± 0.7 μg/mL, T max was 2 hours, AUC was 12.5 ± 1.6 μg × h/mL, and t1/2 was 1.54 ± 0.20 hours.Citation43

Pharmacodynamics

By relating pharmacokinetic variables and susceptibility data (ie, antibiotic drug exposure relative to in vitro MIC), PK/PD breakpoints indicate the highest MIC that produces the adequate value for the relevant PK/PD parameter predicting bacterial killing, eradication, and clinical outcome. In the case of cefditoren, pharmacodynamics in relation to community-acquired respiratory tract infections should be studied especially for S. pneumoniae, since H. influenzae and S. pyogenes are uniformly and highly susceptible to cefditoren. For cefditoren, as for β-lactams, the time (t) (expressed as percentage of the dosing interval) that antibiotic concentrations exceed the value of MIC (t > MIC) is the index predicting efficacy with a cut-off value of 40% for clinical cure in humans,Citation44,Citation45 although a t > MIC of 33% has been used as bacteriostatic endpoint and susceptibility is defined by the FDA and CLSI as inhibition by usually achievable concentrations of the recommended dose.Citation17,Citation46

Data from a phase I study in Caucasians showed that the 400 mg twice daily regimen of cefditoren pivoxil gave a value of t > MIC for total drug of about 55% for MIC of 0.5 μg/mL, 68% for MIC of 0.25 μg/mL, 81% for MIC of 0.12 μg/mL, and 94% for MIC of 0.06 μg/mL.Citation43 Classically the unbound fraction of an antimicrobial has been considered the active fraction in vitro; however the reversibility of protein binding implies that limitation of activity may be far from absolute, even in highly protein bound agents.Citation47 For cefditoren, which exhibits 88% protein binding,Citation37 this could be postulated as a limitation to its in vivo intrinsic activity. Considering that protein binding rates in humans and mice are equal for cefditoren, the extrapolation to humans of pharmacodynamic data obtained in animal models acquires special interest. A pneumococcal sepsis model in mice infected by strains with exceptionally high cefditoren MIC (1–2 μg/mL) showed that cefditoren t > MIC of ≈35% (free t > MIC of ≈20%) produced 100% survival in contrast to placebo (0% survival).Citation48 Free t > MIC of ≈20% was also related to >99.9% reduction in bacterial load (of 2 isolates serotypes 6B and 15A with MIC = 0.25 μg/mL) in an in vitro pharmacodynamic simulation with physiological albumin concentrations and 86% protein binding rate in the device.Citation49 In a cefditoren Monte Carlo simulation (using data determined in the phase I studyCitation43) considering 33% t > MIC (bacteriostatic endpoint) as endpoint value (approximately the value obtained in the mice model for total drug), strains with MICs up to 0.5 μg/mL were covered by cefditoren.Citation46 When applying free drug 33% t > MIC (a value higher than the one required in the mice model for 100% survival and in the pharmacodynamic simulation for >99.9% reduction in bacterial load), strains up to 0.25 μg/mL were covered.Citation46 If the classical theoretical value of free t > MIC of 40% was considered, strains up to 0.12 μg/mL were covered by cefditoren in the Monte Carlo simulation.Citation46

According to these data, the cefditoren breakpoint for nonsusceptibility should be within the range ≤0.12 μg/mL and ≤0.5 μg/mL. This latter value has been proposed by several authors considering cefditoren MIC90 values lower than the breakpoints values for parenteral third-generation cephalosporins and the pharmacokinetics of cefditoren,Citation50Citation52 and was the breakpoint approved by the Spanish Agency during the registration procedure in Europe (susceptibility ≤0.5 μg/mL).Citation53 The most conservative breakpoint (≤0.12 μg/mL) has been proposed by the FDA.Citation54 With this breakpoint, 94.9% of S. pneumoniae isolates in Spain in 2006–2007 are covered.Citation15

An interesting pharmacodynamic result for cefditoren in the above-mentioned mice model was the decrease in the required t > MIC values producing efficacy when animals were passively immunized (with nonprotective levels of specific antibodies) prior to infection. The required values of t > MIC linked to efficacy decreased from ≈35% (free t > MIC of ≈20%) in nonimmunized animals to ≈25% (free t > MIC of ≈15%) in the immunized ones.Citation48 This is interesting in the context where specific antibodies (at nonprotective levels) are likely to be present before S. pneumoniae infection, since colonization is to some extent a B-cell immunizing eventCitation55,Citation56 and preventive measures such as pneumococcal vaccination are increasingly been used in the community. The benefit of these findings would not be the decrease of administered doses, but rather the coverage by current regimens of the exceptional strains with high MIC values.

Cefditoren has shown a postantibiotic effect greater than 1 hour for S. pneumoniae and S. pyogenes, which also supports the twice daily regimen for the treatment of respiratory tract infections.Citation57

Efficacy clinical studies with cefditoren in the treatment of upper respiratory tract infections

During the clinical development of cefditoren, 3 comparative multicenter studies were performed with cefditoren and penicillin V as comparator in pharyngotonsillitis in patients ≥12 years of age. The three studies included a total of 1322 randomized patients, with 1241 patients in the intention-to-treat (ITT) analysis and 1010 patients in the per-protocol (PP) population. In the pooled analysis of the three studies, no significant differences in clinical response were found between cefditoren and penicillin V, success rates ranging from 89.4% to 95.3%.Citation58 Eradication of S. pyogenes was higher with cefditoren at the end of therapy (90.4% vs 82.7%; P = 0.002) and at the end of follow-up (84.7% vs 76.7%; P = 0.008), although the statistical significance set at P < 0.001 was not reached.Citation58

Two additional studies have been recently published for cefditoren in the treatment of group A β-hemolytic streptococcal pharyngotonsillitis in children.Citation59,Citation60 Ozaki et al reported a study comparing 3 mg/kg cefditoren-pivoxil 3 times daily for 5 days versus amoxicillin 10 mg/kg 3 times daily for 10 days in 258 patients (258 isolates with amoxicillin and cefditoren MIC ≤ 0.06 μg/mL).Citation59 Eradication was 100% with amoxicillin and 99% with cefditoren pivoxil, with no differences in the recurrence rate (15 patients in the amoxicillin arm and 8 patients in the cefditoren arm).Citation59 The second study compared the efficacy provided by 9 mg/kg cefditoren pivoxil (maximum dose 300 mg/day) 3 times daily for 5 days (77 patients) versus 10 days (149 patients) in children with history of at least 1 episode of group A β-hemolytic streptococcal pharyngotonsillitis.Citation60 Similar bacteriological failure occurred in both arms (9.1% vs 11.4%), but significantly higher recurrences were found in the 5 days treatment group (9.1% vs 0.7%; P = 0.03).Citation60

Three studies were carried out in adults with acute sinusitis during the clinical development of cefditoren, using cefuroxime or amoxicillin/clavulanic acid as comparators. The three studies included 1819 randomized patients: 1726 patients included in the ITT and 1589 patients in the PP population. In the pooled analysis of the three studies, no differences in clinical response were found between cefditoren and comparators both at the end of therapy (80.2% vs 84.8%) and at the end of follow-up (71.2% vs 77.4%).Citation58 An additional study in the treatment of bacterial rhinosinusitis in children was recently published comparing 4 to 6 mg/kg twice daily (maximum dose 300 mg/day) versus 80 to 90 mg/kg (on amoxicillin basis) amoxicillin/clavulanic acid (maximum dose 800 mg/day) twice daily for 14 days.Citation61 Rates of improvement were similar in both groups (78.8% vs 84.7%) with similar relapse rates (9.1% vs 11.1%) or recurrences (3.0% vs 5.6%) of sinus symptoms.Citation61

Efficacy clinical studies with cefditoren in the treatment of community-acquired lower respiratory tract infections

Seven studies were carried out in the clinical development of cefditoren in the treatment of lower respiratory tract infections, 4 studies in community-acquired pneumonia (CAP) and 3 studies in acute exacerbation of chronic bronchitis (AECB). A pooled analysis of data was performed including a total of 4159 randomized patients.Citation62 Comparators were amoxicillin/clavulanic acid or cefpodoxime in CAP studies, and cefuroxime or clarithromycin in AECB studies. Pooled data from CAP studies revealed no significant differences in response rates between cefditoren and comparators, percentages of responders ranging from 89.2% to 91.8% at the end of therapy and from 85.9% to 90.4% at the end of follow-up.Citation62 Pooled data from the AECB studies resulted in response rates ranging from 85.8% to 91.3% at the end of therapy and from 81.2% to 83.3% at the end of follow-up, without significant differences between groups.Citation62

For microbiological assessment, data from CAP and AECB studies were pooled. Globally, the bacteriologically evaluable population consisted of 1910 patients with 1223 target pathogens isolated prior to treatment initiation, including 406 S. pneumoniae isolates (56 of them nonsusceptible to oral penicillin) and 595 H. influenzae isolates.Citation62 No significant differences were found in the rate of bacteriological responders for S. pneumoniae, percentages ranging from 88.5% to 92.0%. Among penicillin nonsusceptible (MIC ≥ 0.12 μg/mL) S. pneumoniae isolates, all 20 (100%) strains in the cefditoren 400 mg group, 84.2% (16 out of 19) strains in the cefditoren 200 mg group, and 94.1% (16 out of 17) strains in the comparator group were eradicated or presumed eradicated.Citation62 Among penicillin-resistant (MIC ≥ 2 μg/mL) isolates, 17 (94.4%) of 18 isolates in both cefditoren arms were eradicated or presumed eradicated, compared with 10 (90.9%) of 11 in the comparator group.Citation62 Differences in the rate of responders for H. influenzae were also not significant (range 82.7% to 86.6%).Citation62

Bacterial eradication as a goal of antibacterial treatment, and subsequent clinical efficacy

The correlation between bacterial eradication and clinical outcome in respiratory tract infections can be explored in streptococcal tonsillopharyngitis as an upper respiratory tract infection and AECB as a lower respiratory tract infection, since noninvasive samples for culture are easily collected over time. As noted in the previous section, in the pooled analysis of studies on tonsillopharyngitis bacteriological efficacy was associated with a higher clinical response rate.Citation58 Cefditoren (a β-lactamase-resistant cephalosporin) showed a tendency of higher bacteriological response for S. pyogenes than penicillin (susceptible to β-lactamases produced by commensal flora),Citation58 reinforcing the concept of “co-pathogenicity” with β-lactamase-producing bacteria. It has been hypothesized that β-lactamase from β-lactamase-producing isolates such as H. influenzae may protect non-β-lactamase-producing isolates such as S. pyogenes from the action of the antibiotic.Citation63,Citation64 In this sense, a previous meta-analysis also showed higher bacteriological failures with penicillins versus cephalosporins.Citation65 Co-pathogenicity was also explored in vitro in a pharmacodynamic simulation of free concentrations over 24 hours obtained with 875 mg amoxicillin 3 times daily, 875/125 mg amoxicillin/clavulanic acid 3 times daily, and 400 mg cefditoren twice daily using individual and mixed inocula (proportions 1:1:1:1) of 1 S. pyogenes isolate, 1 penicillin-resistant S. pneumoniae, 1 β-lactamase positive H. influenzae, and 1 BLPACR H. influenzae isolate.Citation66 At 24 hours amoxicillin was able to eradicate S. pyogenes in simulations carried out with the individual S. pyogenes inoculum but failed to do so in simulations with the mixed inocula where S. pyogenes was protected by β-lactamases produced by the H. influenzae isolates.Citation66 In contrast S. pyogenes was eradicated by cefditoren, both in individual and mixed simulations where both strains of H. influenzae were also eradicated.Citation66

One of the AECB studies included in the pooled analysis of lower respiratory tract infectionsCitation62 exploring the relationship of bacteriological and clinical responses has been individually published.Citation67 In this study, including 541 patients, inclusion criteria, baseline characteristics of patients (age and pre-study smoking history), and the required symptoms of exacerbation (Anthonisen I and II) ensured inclusion of patients with underlying chronic bronchitis, and increased the chance of the bacterial origin of the exacerbation. Improvement/efficacy was more evident in signs linked to the presence of bacteria, such as rales, ronchi, and the volume and purulence of the sputum (which decreased from about 80% patients in the pre-treatment visit to about 10% patients at day 30) than in signs linked to chronic structural damage such as dyspnea which decreased from only about 99% in the pre-treatment visit to 75% patients at day 30.Citation67 Globally, per-pathogen bacterial response related well to clinical success: 83.5% isolates (out of 164 baseline isolates) from patients resulting in clinical response were eradicated or presumably eradicated in contrast to only 3% isolates (out of 33 baseline isolates) from patients resulting in clinical failure.Citation67

Safety data from clinical trials performed during the clinical development of cefditoren

Safety data from all the 13 clinical trials carried out during the clinical development of cefditoren for the treatment of community-acquired respiratory infections were analyzed in a pooled analysis.Citation68 Safety population was defined as all randomized patients with at least 1 dose intake, and comprised 4592 patients for cefditoren.Citation68 Cefditoren exhibited an adverse event profile similar to that of previous antibiotics currently used in the treatment of community-acquired respiratory tract infections, diarrhea being the most frequent adverse event (9.9%) followed by vaginosis (3.9% among female population), nausea (3.5%), abdominal pain (1.8%), and dyspepsia (1.1%).Citation68

Conclusions

The pharmaceutical industry has decreased its efforts to develop new antimicrobials, and the lack of a robust pipeline of new compounds has been suggested.Citation69 In this situation, the fact that the main ecological effect of antimicrobials is promoting the emergence of resistanceCitation70 (a risk associated with the imprudent use of available drugs) implies that clinicians may have limited options within the current armamentarium. Since the use of agents to which pathogens are resistant contributes to increased morbidity, mortality, and associated expenses,Citation71 the rational use of antibiotics can help to stop or minimize the emergence, spread, and diversification of antibiotic resistance.

In this context, this article reviews and updates published data on cefditoren in the evolving situation of resistance among the most prevalent isolates from respiratory tract infections in the community. By relating its in vitro activity (from surveillance and in vitro studies including isolates with emerging resistant genotypes/phenotypes) to its pharmacokinetics, the cefditoren pharmacodynamic activity predicting therapeutic efficacy (in humans, animal models, and in vitro simulations) was analyzed prior to reviewing clinical studies and the relationship between bacterial eradication and therapeutic efficacy. The wide range of studies carried out with cefditoren constitutes one of the most extensive and continuous sources of data defining the role of a new antibiotic in the community and provides information to clinicians (on cefditoren and comparators) of relevance to establish empirical therapy.

The high in vitro activity of cefditoren against the most prevalent respiratory isolates in the community, together with its pharmacokinetics (allowing a twice daily regimen) leading to adequate pharmacodynamic indexes covering all S. pyogenes, H. influenzae, and 94.9% S. pneumoniae isolates, makes cefditoren an antibiotic that will play a significant role in the treatment of respiratory tract infections in the community. In the clinical setting, studies carried out with cefditoren showed that treatments with the 400 mg twice daily regimen were associated with high rates of bacteriological response, even against penicillin nonsusceptible S. pneumoniae, with good correlation between bacteriological efficacy/response and clinical outcome.

Disclosure

The authors declare no conflicts of interest.

References

  • MogyorosMChallenges of managed care organisations in treating respiratory tract infections in an age of antibiotic resistanceAm J Man Care20017Suppl 6163169
  • LlorCConsideraciones a la hora de la prescripción antibiótica en atención primariaMed Clin Monogr (Barc)200455257
  • HuovinenPCarsOControl of antimicrobial resistance: time for action. The essentials of control are already well knownBMJ19983176136149727984
  • García-ReyCFenollAAguilarLCasalJEffect of social and climatological factors on antimicrobial use and Streptococcus pneumoniae resistance in different provinces in SpainJ Antimicrob Chemother20045446547115269198
  • GranizoJJAguilarLCasalJGarcía-ReyCDal-RéRBaqueroFStreptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979–1997)J Antimicrob Chemother20004676777311062196
  • García-ReyCAguilarLBaqueroFCasalJDal-RéRImportance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniaeJ Clin Microbiol20024015916411773111
  • GómezJRuiz-GómezJHernández-CardonaJLNuñezMLCanterasMValdésMAntibiotic resistance patterns of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a prospective study in Murcia, Spain, 1983–1992Chemotherapy1994402993037956452
  • GranizoJJAguilarLCasalJDal-RéRBaqueroFStreptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986–1997)J Antimicrob Chemother20004695996411102415
  • García-ReyCAguilarLBaqueroFCasalJMartínJEPharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in SpainJ Clin Microbiol2002402959296312149359
  • Pérez-TralleroEGarcía-de-la-FuenteCGarcía-ReyCGeographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in SpainAntimicrob Agents Chemother2005491965197215855520
  • Gómez-LusRGranizoJJAguilarLBouzaEGutierrezAGarcía-de-LomasJIs there an ecological relationship between rates of antibiotic resistance of species of the genus Streptococcus? The Spanish Surveillance Group for Respiratory PathogensJ Clin Microbiol1999373384338610488213
  • RichterSSHeilmannKPBeekmannSEMacrolide-resistant Streptococcus pyogenes in the United States, 2002–2003Clin Infect Dis20054159960816080080
  • ChanJCChuYWChuMYCheungTKLoJYEpidemiological analysis of Streptococcus pyogenes infections in Hong KongPathology20094168168620001348
  • GraciaMDíazCCoronelPAntimicrobial susceptibility of Streptococcus pyogenes in Central, Eastern, and Baltic European Countries, 2005 to 2006: the cefditoren surveillance programDiagn Microbiol Infect Dis200964525619232860
  • Pérez-TralleroEMartín-HerreroJEMazónAAntimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996–1997 to 2006–2007)Antimicrob Agents Chemother2010542953295920439616
  • PrietoJCalvoAGómez-LusMLAntimicrobial resistance: a class effect?J Antimicrob Chemother200250Suppl S2712
  • Clinical and Laboratory Standards InstitutePerformance standards for antimicrobial susceptibility testing; nineteenth informational supplement. CLSI document M100-S19Clinical and Laboratory Standards InstituteWayne, PA USA2009
  • SahmDFBrownNPThornsberryCJonesMEAntimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspectivePostgrad Med20081203 Suppl 1162418931467
  • SahmDFBrownNPDraghiDCEvangelistaATYeeYCThornsberryCTracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001–2005Postgrad Med20081203 Suppl 181518931466
  • JansenWTVerelABeitsmaMVerhoefJMilatovicDLongitudinal European surveillance study of antibiotic resistance of Haemophilus influenzaeJ Antimicrob Chemother20065887387716891323
  • SevillanoDGiménezMJCercenadoEGenotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markersAntimicrob Agents Chemother20095326727018955529
  • NikiYHanakiHMatsumotoTNationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens’ antibacterial susceptibilityJ Infect Chemother20091515616719554400
  • SakataHToyonagaYSatoYNationwide survey of the development of drug-resistance in the pediatric field: drug sensitivity of Haemophilus influenzae in JapanJ Infect Chemother20091540240920012732
  • PericMBozdoganBJacobsMRAppelbaumPCEffects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolatesAntimicrob Agents Chemother2003471017102212604536
  • CantónRUnalSFarrellDJAntibacterial resistance patterns in Streptococcus pneumoniae isolated from elderly patients: PROTEKT years 1–5 (1999–2004)Int J Antimicrob Agents20073054655017931834
  • DarabiAHocquetDDowzickyMJAntimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance TrialDiagn Microbiol Infect Dis201067788620385351
  • Pérez-TralleroEGarcía-de-la-FuenteCGarcía-ReyCGeographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in SpainAntimicrob Agents Chemother2005491965197215855520
  • FenollAGranizoJJAguilarLTemporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007J Clin Microbiol2009471012102019225097
  • FenollAAguilarLGranizoJJHas the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae?J Antimicrob Chemother2008621430143318819966
  • WhitneyCGFarleyMMHadlerJDecline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccineN Engl J Med20033481737174612724479
  • FenollAAguilarLGiménezMJSusceptibility of recently collected Spanish pneumococci nonsusceptible to oral penicillin from serotypes not included in the 7-valent conjugate vaccineAntimicrob Agents Chemother2010542696269820308373
  • FenollAAguilarLViciosoMDSerotype distribution and susceptibility of Streptococcus pneumoniae isolates from pleural fluid in the current decade in SpainAntimicrob Agents Chemother2010545387539020921314
  • PicazoJRuiz-ContrerasJCasado-FloresJRelations between serotypes, age and clinical presentation of invasive pneumococcal disease in Madrid after the introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendarClin Vaccine Immunol201118899421047996
  • Pérez-TralleroEMarimónJMErcibengoaMGiménezMJCoronelPAguilarLAntimicrobial susceptibilities of amoxycillin-non-susceptible and susceptible isolates among penicillin-non-susceptible Streptococcus pneumoniaeClin Microbiol Infect20071393794017617182
  • SorianoFCafiniFAguilarLBreakthrough in penicillin resistance? Streptococcus pneumoniae isolates with penicillin/cefotaxime MICs of 16 mg/L and their genotypic and geographical relatednessJ Antimicrob Chemother2008621234124018799472
  • Rodríguez-CerratoVGraciaMDel PradoGAntimicrobial susceptibility of multidrug-resistant Streptococcus pneumoniae strains with penicillin MICs of 8 to 32 mg/LDiagn Microbiol Infect Dis20106633633819939599
  • WellingtonKCurranMPCefditoren pivoxil: a review of its use in the treatment of bacterial infectionsDrugs2004642597261815516158
  • YamadaMWatanabeTMiyaraTCrystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activityAntimicrob Agents Chemother2007514550
  • GraciaMDíazCCoronelPAntimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis isolates in eight Central, East and Baltic European countries in 2005–06: results of the Cefditoren Surveillance StudyJ Antimicrob Chemother2008611180118118316820
  • García-de-LomasJLermaMCebriánLInfluence of Haemophilus influenzae beta-lactamase production and/or ftsI gene mutations on in vitro activity of and susceptibility rates to aminopenicillins and second- and third-generation cephalosporinsInt J Antimicrob Agents20073019019217459665
  • SorianoFGranizoJJFenollAAntimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: results from the cefditoren surveillance programJ Chemother20031510711212797384
  • SorianoFCoronelPGimenoMJiménezMGarcía-CorbeiraPFernández-RoblasRInoculum effect and bactericidal activity of cefditoren and other antibiotics against Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidisEur J Clin Microbiol Infect Dis1996157617638922582
  • SádabaBAzanzaJRQuetglasEGPharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I studyRev Esp Quimioter200720516017530036
  • CraigWAPharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and menClin Infect Dis1998261109455502
  • HeffelfingerJDDowellSFJorgensenJHManagement of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working GroupArch Intern Med20001601399140810826451
  • GranizoJJSádabaBHonoratoJMonte Carlo simulation describing the pharmacodynamic profile of cefditoren in plasma from healthy volunteersInt J Antimicrob Agents20083139639818178067
  • MoelleringRCEliopoulosGMPrinciples of anti-infective therapyMandellGLBennettJEDolinRMandell, Douglas, and Bennett Principles and Practice of Infectious Diseases6th edPhiladelphiaElsevier Churchill Livingstone2005242253
  • CafiniFYusteJGiménezMJEnhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis modelPLoS One201058e1204120706584
  • SevillanoDAguilarLAlouLHigh protein binding and cidal activity against penicillin-resistant S. pneumoniae: a cefditoren in vitro pharmacodynamic simulationPLoS One200837e271718648650
  • KarlowskyJAJonesMEDraghiDCCritchleyIAThornsberryCSahmDFIn vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditorenDiagn Microbiol Infect Dis200242596411821173
  • JohnsonDMBiedenbachDJBeachMLPfallerMAJonesRNAntimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus speciesDiagn Microbiol Infect Dis2000379910510863104
  • JonesRNBiedenbachDJCrocoMABarrettMSIn vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniaeDiagn Microbiol Infect Dis1998315735789764398
  • Agencia Española de Medicamentos y Productos Sanitarios https://sinaem4.agemed.es/consaem/fichasTecnicas.do?metodo=detalleForm.
  • Food and Drug AdministrationSpectracef prescribing information http://www.crtx.com/docs/spectracef.pdf.
  • WeinbergerDMDaganRGivon-LaviNEpidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriageJ Infect Dis20081971511151818471062
  • SoininenAPursiainenHKilpiTKäyhtyHNatural development of antibodies to pneumococcal capsular polysaccharides depends on the serotype: association with pneumococcal carriage and acute otitis media in young childrenJ Infect Dis200118456957611494163
  • FelminghamDRobbinsMJGhoshGAn in vitro characterization of cefditoren, a new oral cephalosporinDrugs Exp Clin Res1994201271477813385
  • GranizoJJGiménezMJBarberánJCoronelPGimenoMAguilarLEfficacy of cefditoren in the treatment of upper respiratory tract infections: a pooled analysis of six clinical trialsRev Esp Quimioter200821142118443928
  • OzakiTNishimuraNSuzukiMFive-day oral cefditoren pivoxil versus 10-day oral amoxicillin for pediatric group A streptococcal pharyngotonsillitisJ Infect Chemother20081421321818574657
  • KikutaHShibataMNakataSComparative study of 5-day and 10-day cefditoren pivoxil treatments for recurrent group A beta-hemolytic Streptococcus pharyngitis in childrenInt J Pediatr200986360820041005
  • PoachanukoonOKitcharoensakkulMEfficacy of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigator-blinded, controlled trialClin Ther2008301870187919014842
  • GranizoJJGiménezMJBarberánJCoronelPGimenoMAguilarLThe efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trialsClin Ther2006282061206917296462
  • CaseyJRPichicheroMEThe evidence base for cephalosporin superiority over penicillin in streptococcal pharyngitisDiagn Microbiol Infect Dis2007573 SupplS39S45
  • BudhaniRKStruthersJKInteraction of Streptococcus pneumoniae and Moraxella catarrhalis: investigation of the indirect pathogenic role of beta-lactamase-producing moraxellae by use of a continuous-culture biofilm systemAntimicrob Agents Chemother199842252125269756750
  • CaseyJRPichicheroMEMeta-analysis of cephalosporins versus penicillin for treatment of group A streptococcal tonsillopharyngitis in adultsClin Infect Dis2004381526153415156437
  • SevillanoDAguilarLAlouLBeta-lactam effects on mixed cultures of common respiratory isolates as an approach to treatment effects on nasopharyngeal bacterial population dynamicsPLoS One2008312e384619052648
  • Alvarez-SalaJLKardosPMartínez-BeltránJCoronelPAguilarLClinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetilAntimicrob Agents Chemother2006501762176716641447
  • GranizoJJAguilarLGimenezMJCoronelPGimenoMPrietoJSafety profile of cefditoren. A pooled analysis of data from clinical trials in community-acquired respiratory tract infectionsRev Esp Quimioter200922576119544097
  • AlmiranteBCamposJCantónRPrudent use of antimicrobials: have we done the best we can? The SEIMC and REIPI statementEnferm Infecc Microbiol Clin20102848548620817357
  • BaqueroFGarauJPrudent use of antimicrobial agents: revisiting concepts and estimating perspectives in a global worldEnferm Infecc Microbiol Clin20102848748820846754
  • DanemanNLowDEMcGeerAGreenKAFismanDNAt the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumoniaClin Infect Dis2008461131113818444846